- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07848165
Probiotic Role in Prevention of Ventilator Associated Pneumonia in Critically- Ill Children Admitted at Pediatric Intensive Care Unit
Assessment of Probiotic Role in Prevention of Ventilator Associated Pneumonia in Critically- Ill Children Admitted at Pediatric Intensive Care Unit
The aim of the work is to evaluate the impact of Probiotics supplementation on prevention of ventilator associated pneumonia in critically ill children admitted at Pediatric Intensive Care Unit at Tanta University Hospitals.
Study Overview
Status
Intervention / Treatment
Detailed Description
Critically ill children are the children whom requiring, or potentially requiring, high reliance or serious consideration whether in medical, surgical or trauma-related fields.
Based on the time of onset of Ventilator Associated Pneumonia (VAP), it can be divided into two types. Early-onset VAP occurs during the first four days of mechanical ventilation and is usually caused by antibiotic sensitive bacteria. Late-onset VAP develops five or more days after initiation of MV and is caused by multidrug-resistant (MDR) pathogens .VAP is associated with a high rate of all-cause mortality and a prolonged duration of mechanical ventilation and intensive care unit stay.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yomna G El-Feky, MD
- Phone Number: 00201005562005
- Email: Youmna.elfeky@med.tanta.edu.eg
Study Locations
-
-
Al Gharbia
-
Tanta, Al Gharbia, Egypt, 31739
- Recruiting
- Tanta University
-
Contact:
- Yomna G El-Feky, MD
- Phone Number: 00201005562005
- Email: Youmna.elfeky@med.tanta.edu.eg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Critically ill children from 1 month to 18 years.
- Both sexes.
- Ventilated not due to chest infection.
Exclusion Criteria:
- Children recently received enteral vaccines.
- Children receiving chronic immunosuppressive such as chemotherapy agents. and immunosuppressive medications, and high dose corticosteroids (more than 1 milligram per kilogram).
- Children with contraindications of enteral feeding.
- Children with gastrointestinal bleeding.
- Children with open wounds following major surgery.
- Children with short gut syndrome.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group I
Critically ill ventilated children will receive standard management plus probiotics. |
Critically ill ventilated children will receive standard management plus probiotics. |
|
Active Comparator: Group II
Critically ill ventilated children will receive standard management only. |
Critically ill ventilated children will receive standard management only. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of ventilator-associated pneumonia
Time Frame: During the first 28 days after initiation of mechanical ventilation
|
Incidence of ventilator-associated pneumonia (VAP) diagnosed according to predefined CDC/NHSN pediatric criteria |
During the first 28 days after initiation of mechanical ventilation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of mechanical ventilation
Time Frame: Up to 28 days
|
Duration of invasive mechanical ventilation will be measured in days from initiation of mechanical ventilation until successful extubation. |
Up to 28 days
|
|
Pediatric intensive care unit length of stay
Time Frame: Up to 28 days
|
Pediatric intensive care unit (PICU) length of stay will be measured in days from PICU admission until PICU discharge. |
Up to 28 days
|
|
Incidence of mortality
Time Frame: Up to 28 days
|
Incidence of mortality will be recorded. |
Up to 28 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Healthcare-Associated Pneumonia
- Pathologic Processes
- Disease Attributes
- Respiratory Tract Infections
- Infections
- Respiratory Tract Diseases
- Lung Diseases
- Pneumonia
- Cross Infection
- Iatrogenic Disease
- Pathological Conditions, Signs and Symptoms
- Pneumonia, Ventilator-Associated
- Dietary Supplements
- Food
- Diet, Food, and Nutrition
- Physiological Phenomena
- Food and Beverages
- Probiotics
Other Study ID Numbers
- 36264MS985/6/25
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
IPD Sharing Time Frame
After the end of study for one year.
IPD Sharing Access Criteria
The data will be available upon a reasonable request from the corresponding author.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.